AI Prospecting for Eli Lilly
Company data:
Company size:
43000 employeesWebsite URL:
https://www.lilly.comIndustry
PharmaceuticalsHeadquarters:
Indianapolis, Indiana, USAInvestment round:
Publicly Traded (NYSE: LLY)ARR:
$23 billionKey stakeholders
These are the current top-level decision-makers at the company and their LinkedIn profiles. Check them for recent activity and updates
Latest news about Eli Lilly
Here are some of the most recent media mentions. Use them in your sales prospecting to qualify a prospect's buyer intent and personalize outreach with the latest company updates
Eli Lilly's Zepbound (tirzepatide) demonstrated a 47% greater relative weight loss compared to Novo Nordisk's Wegovy (semaglutide) in the Phase 3b SURMOUNT-5 trial, with patients on Zepbound losing 50.3 lbs (22.8 kg) versus 33.1 lbs (15.0 kg) on Wegovy over 72 weeks[2][3][4].
Eli Lilly reported a 20% increase in Q3 2024 revenue to $11.44 billion, driven by volume growth from Mounjaro and Zepbound, and a 17% increase in non-incretin revenue. The company also announced approvals for Ebglyss in the U.S. for atopic dermatitis and Kisunla in Japan for early symptomatic Alzheimer's disease[1].
Eli Lilly declared a fourth-quarter 2024 dividend of $1.30 per share, payable on December 10, 2024, to shareholders of record at the close of business on November 15, 2024[3][4].
Open job positions at Eli Lilly
This company is actively hiring to fill these roles. Use this for sales prospecting if your solution assists, augments, or provides an alternative for the growing team and position.
